Company Filing History:
Years Active: 2024
Title: Inventor Spotlight: Nicolas Joly-Tonetti
Introduction
Nicolas Joly-Tonetti, an innovative inventor based in Suisse, CH, has made notable contributions in the field of oncology-related skin care. With a focus on developing methodologies to improve patient comfort during cancer treatment, he has secured a patent that addresses important aspects of dermatological care amidst cancer therapeutics.
Latest Patents
Joly-Tonetti holds a patent titled "Method for evaluating the efficacy of a composition in reducing the effects of cancer therapeutics on skin." This patent introduces an epidermal tridimensional model featuring differentiating keratinocytes in a reconstituted stratum corneum model. The significance of this invention lies in its ability to simulate chronic drug exposure through the inclusion of a cancer therapeutic, allowing for the evaluation of potential skin-related side effects associated with such treatments. Furthermore, this method can assess the effectiveness of various compositions aimed at alleviating these adverse effects.
Career Highlights
Currently, Nicolas Joly-Tonetti is making strides in his career at Johnson & Johnson Consumer Inc., a leading global company renowned for its commitment to health and wellness. His work focuses on the integration of scientific advancements to enhance the therapeutic experience for cancer patients.
Collaborations
Throughout his career, Joly-Tonetti has collaborated with esteemed colleagues, including Thomas Ondet and Mario Monshouwer. These partnerships within the research and development sector contribute to the innovation and efficacy of the projects he undertakes, advancing the boundaries of cancer treatment and patient care.
Conclusion
Nicolas Joly-Tonetti exemplifies the spirit of innovation through his groundbreaking patent that addresses the needs of cancer patients experiencing skin complications from treatment. His work at Johnson & Johnson Consumer Inc. and collaborations with other professionals demonstrate a strong commitment to improving healthcare outcomes. As cancer therapeutics evolve, the importance of such advancements in patient care continues to grow, positioning Joly-Tonetti as a valued contributor in the field.